This excerpt taken from the SLXP 8-K filed Jun 2, 2009.
A post hoc analysis of two clinical trials (n=562) revealed that the majority of a sub-population of patients (n=158) who had previously received corticosteroid therapy to treat UC flares or to maintain UC remission, remained in remission after treatment with APRISO (1.5 g). Of the patients who had previously received corticosteroids, 77 percent of patients treated with APRISO did not experience a relapse, compared to 55 percent of patients receiving placebo (P=0.006). Further, according to the Kaplan-Meier log-rank statistics, the probability of patients remaining relapse-free without further corticosteroid treatment was significantly higher in those treated with APRISO, versus placebo. The probability of remaining relapse-free for the corticosteroid subpopulation was comparable to the entire study population (Poster #T1202). Limiting exposure to steroids is important for these patients who may require long-term treatment.